** Shares of cancer drug developer MAIA Biotechnology MAIA.A rise 16.4% to $2.20

** Co says its experimental drug, THIO, helped patients with a type of lung cancer live for a median of 16.9 months, in mid-stage trial

** THIO was generally well-tolerated in patients who had received multiple previous treatments, co says

** Co says it is considering the possibility of accelerated FDA approval of THIO

** THIO gained 66.4% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))